CUE vs INTC · rev $9.3M vs rev $52.85B
Cue Biopharma (CUE) versus Intel Corporation (INTC) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Intel Corporation (INTC) is a semiconductors company listed on US. It is led by Pat Gelsinger.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported INTC revenue for 2025-12-27 was $52.85B. Net income was -$267.0M. Revenue was down 0.5% from 2024-12-28 to 2025-12-27. INTC currently screens at market cap $498.43B.
CUE currently screens at market cap $59.5M. INTC currently screens at market cap $498.43B.
Not investment advice. Open the CUE and INTC stock pages for the full models.
Not investment advice.